Copyright bbc
Johnson & Johnson spun off Kenvue as a standalone company in 2023, separating its faster growing, more profitable medical technical and pharmaceutical business from its consumer products. Executives argued at the time that a narrower focus would help each company flourish. But Kenvue's business and its shares have struggled, down almost 30% in a year, making it a target of activist investors, who have bought up stakes and pushed the firm for changes, including a possible sale. The firm's shares sank last month, when the Trump administration publicly linked use of Tylenol during pregnancy to autism, despite what scientists say is inconclusive evidence. Sales in the first nine months of the year are down almost 4% compared with 2024.
